Expand all sections

Pembrolizumab

Keytruda

Extended indication Extension of indication to include a new indication for Keytruda, in combination with chemotherapy,
Therapeutic value No estimate possible yet
Total cost 6,750,000.00
Registration phase Registration application pending

Product

Active substance Pembrolizumab
Domain Oncology and Hematology
Reason of inclusion Indication extension
Main indication Oncology other
Extended indication Extension of indication to include a new indication for Keytruda, in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in adults.
Proprietary name Keytruda
Manufacturer MSD
Mechanism of action PD-1 / PD-L1 inhibitor
Route of administration Intravenous
Therapeutical formulation Infusion fluid
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Submission date October 2021
Expected Registration June 2022
Orphan drug No
Registration phase Registration application pending
Additional remarks Fabrikant verwacht indiening in 2021 en registratie in het tweede kwartaal van 2022.

Therapeutic value

Therapeutic value No estimate possible yet
Frequency of administration 1 times every 3 weeks
Dosage per administration 200mg
References SMPC Keytruda, NCT03635567.
Additional remarks - Bij mono therapie eenmaal in de 6 weken 400mg mogelijk; - tot maximaal 2 jaar behandeling.

Expected patient volume per year

Patient volume

70 - 80

Market share is generally not included unless otherwise stated.
References DGOG
Additional remarks Er wordt verwacht dat er 70-80 patiënten in aanmerking zullen komen voor deze behandeling. Deze inschatting is gedaan op basis van huidige getallen van bevacizumab bij cervixcarcinoom.

Expected cost per patient per year

Cost < 90,000.00
References G-standaard
Additional remarks AIP per november 2017: €2.624,38 per injectieflacon 25mg/ml, flacon 4ml (oplossing). Uitgaande van een behandeling van 1 x per 3 weken 200mg voor 12 maanden zou dat gaan om maximaal €90.000 per patiënt per jaar. Voor pembrolizumab is een financieel arrangement van toepassing tot 1 januari 2024. Aankomende indicatie uitbreidingen vallen onder deze overeenkomst, mits zij voldoen aan stand der wetenschap en praktijk.

Potential total cost per year

Total cost

6,750,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension Yes
Indication extensions Indicatie uitbreidingen worden weergegeven in de Horizonscan Geneesmiddelen.
References Fabrikant.

Other information

There is currently no futher information available.